Why Doctors Are Prescribing GLP-1s for Minor Weight Loss

vin.rusanov // Shutterstock Why are more physicians recommending GLP-1 medications for minor weight reduction? Medications such as Ozempic,...

vin.rusanov // Shutterstock

Why are more physicians recommending GLP-1 medications for minor weight reduction?

Medications such as Ozempic, Wegovy, and Zepbound, which target GLP-1, have rapidly gained popularity as aids for individuals struggling with obesity and diabetes to shed weight and manage blood sugar levels. However, new studies indicate that these drugs could also provide longevity-enhancing advantages for those without these specific health issues.

An increasing number of healthcare professionals consider GLP-1 medications as a key component in a comprehensive approachmetabolic healthan optimization initiative, even for individuals who do not satisfy the existing prescription guidelines.

Although GLP-1 medications should not take the place of exercise, diet, sleep, and other positive lifestyle adjustments, weight loss drugs can boost weight reduction and, in numerous instances, help make lifestyle modifications achievable.Hone Health reports.

The Issues with Existing GLP-1 Guidelines

Conventional medical practice typically reserves the prescription of GLP-1 drugs until a patient's BMI reaches 30 (indicating obesity) or 27 along with at least one weight-associated health issue, such ashigh blood pressureor high cholesterol. Doctors may prescribe GLP-1 medications for individuals with BMIs under 27, although insurance typically does not cover the cost.

Unfortunately, BMI—which only measures weight and height—is an inadequate indicator ofbody compositionand general well-being. It is particularly concerning for individuals who fall between the clinical classifications of "overweight" and "obesity." Here's the reasoning:

Muscle mass and bone density can affect BMI readings

BMI does not account for the distinction between muscle mass and body fat. Relying solely on BMI, somevery muscular peoplecould be eligible for GLP-1 therapy according to present FDA regulations, even if it's not necessary. An increasing number of professionals think individuals with BMIs of 25 or 26 who have low muscle mass ("skinny fat") could experience metabolic advantages from the drug.

Individuals with BMIs below 30 may still experience metabolic unhealthiness.

Where you store fat on your body—a measurementBMI doesn’t measure—can make the distinction between healthy and unhealthy.Visceral fat, located near critical organs such as the liver and pancreas, increases inflammation and speeds upbiological agingmore than fat that is located directly beneath the skin. Individuals withmore fat stored around the abdomen ("apple-shaped")tend to have elevated cholesterol levels,blood sugar, and blood pressure at a specific body weight compared to individuals who have fat distributed more uniformly throughout their body ("hourglass" or "pear-shaped").

BMI doesn’t reflect patterns

Two individuals can share the same BMI yet face significantly different health outcomes. Consider two people with the same BMI, where one has a greater amount of muscle compared to the other. The person with more muscle will find it simpler to maintain a consistent weight, while the other may tend to gain weight over time, increasing their risk of developing diabetes.cardiovascular disease. (Most women typically experience weight gain1.5 pounds per year and men typically gain 1 to 2 pounds annuallyin midlife.) Current FDA guidelines suggest waiting until this individual becomes ill or obese (or both) before treating them with a GLP-1 medication. However, halting and reversing this gradual progressionfat gain, early treatment with a GLP-1 may help avoid the chain of health issues that follow.

A New Obesity Definition

Since BMI is a highly flawed measure, the Lancet Commission—comprising 58 experts from various medical fields and countries—suggested in 2025 to redefine "overweight" as "preclinical obesity"—acknowledging that carrying additional weight can be an early sign of health issues.raises the likelihood of various long-term health conditions.

And earlier this year, the European Association for the Study of Obesity (EASO) issued anew obesity definitionthat involves numerous individuals who would have previously been classified as overweight.

Under this new system, individuals with a BMI of 25 or above would be considered to have obesity if they also:

• Possess a waist-to-height ratio of 0.5 or higher
• Have received a diagnosis of medical, functional, or psychological conditions associated with excessive body fat, such as high blood sugar levels,chronic low-grade inflammation, poor sleep, or binge eating.

Approximately one out of every five adults who were previously categorized as overweight would now be classified as obese under the updated EASO criteria—and thus qualify for insurance coverage of GLP-1 therapy, according to astudyappeared in the Annals of Internal Medicine.

The Importance of Even Minor Weight Reduction

Individuals with a BMI between 25 and 30 typically experience a smaller amount of weight loss when using GLP-1 medications, averaging 5%-10% of their body weight, compared to 15%-20% seen in people with clinical obesity.

These minor losses might not appear as significant. However, they can have a substantial impact on long-term outcomes.

Numerous studies have associated minor weight fluctuations with significant health improvements:

• Lowering blood pressure: Decreasing BMI by approximately 2.27 points—such as moving from a BMI of 26 to 23.7, or shedding around 20 pounds—can reduce both systolic and diastolic readings.blood pressureby 5.79 mmHg and 3.36 mmHg,respectively.
• Lessen knee pain: A 5% weight loss is enough to resolve knee pain in some people.
• Lower cancer risk: Shedding as little as 11 pounds can greatly reduce the likelihood of various cancers.cancer, including breast, ovarian, and colon, as reported by ananalysis of 66 studies.
• Reduced risk of diabetes: For individuals with high blood sugar levels, losing 2.2 pounds can decrease the likelihood of developing diabetesdrops 16%. In one study, shedding only 5% of overall body weight was sufficient to enhance the performance of insulin-producing beta cells along with insulin responsiveness.
• Enhance blood lipids: Improvements in triglycerides—fats found in the bloodstream—can begin with as little as2% weight loss. When people lose 5%their body weight, overall and LDLcholesterol levels also improve.
• Promote sounder sleepLosing 5% or more of one's body weight isenough to reducethe count of breathing interruptions individuals with sleep apnea encounter, and also enhancesinsomnia and daytime sleepiness.

GLP-1s facilitate weight lossby reducing the speed at which food moves through the digestive system, enhancing satiety, andsuppressing appetite. Throughout their journey, they help decrease inflammation and act directlysupportcardiovascular, liver, and cerebral well-being, decreasing the intensity of sleep apnea, lowering the likelihood of heart attacks andpremature mortality, easing joint pain, and boosting energy.

Newly developing uses for GLP-1 drugs—such as for heart disease, metabolic liver conditions, peripheral artery disease, Alzheimer's/dementia risk, and even alcohol and substance use disorders, as noted in a2025 study in JAMA—suggest that these medications might soon have a much wider application in medicine beyond just managing diabetes or obesity. Collectively, the evidence indicates a future where access to GLP-1 therapy could increase substantially as guidelines align with scientific advancements.

Why GLP-1 Medications Aren't Considered "Unfair"

Regrettably, an increasing number of healthcare professionals recognize the numerous advantages ofGLP-1 medicinesFor early intervention and improving metabolic health, not everyone is supportive. Many conventional healthcare professionals are unwilling to consider anydiscussion regarding the prescription of GLP-1 medicationsor mockingly tell patients they just need to exert more effort.

However, GLP-1s are not a shortcut or an unfair advantage. In fact, most individuals will not achieve a 5% or greater reduction in body weight without medical intervention.

Studies indicate that roughly one out of ten individuals with a BMI of 25 or above willlose 5% of their physical massand maintain it through lifestyle modifications exclusively.

For the other nine out of ten, a GLP-1 prescription can act as a starting point, enabling them to lose enough weight to facilitate significant lifestyle adjustments. Some view it as providing a fairer chance for those who have genetic predispositions linked to obesity.

Reduced cravings, food noise

"Food noise" is a recently coined phrase that refers to the constant internal dialogue about food, which can result in excessive eating.

GLP-1s help quiet food noiseby affecting the release ofdopaminein the brain's reward center. As the sound of their food diminishes, individuals report they finally gain the mental capacity to adhere tohealthier eating—aiming to consume more vegetables, legumes, and lean proteins, while reducing intake of sweets and chips.

Improved self-confidence

Losing a small amount of weight while on GLP-1 medications, typically between 10 to 30 pounds, frequently leads to significant boosts in self-confidence, which in turn energizeshealthy habitsin a beneficial feedback cycle.

This story was produced by Hone Healthand evaluated and disseminated byHealthy Survival.